Dr Reddys Laboratories (RDY) Net Margin (2009 - 2023)

Dr Reddys Laboratories (RDY) posted quarterly Net Margin of 21.5% for Q2 2023, up 3.16% quarter-over-quarter from 20.84% in Q1 2023.

Dr Reddys Laboratories (RDY) Net Margin (2009 - 2023) Analysis & Trends

Dr Reddys Laboratories' Net Margin history runs 15 years deep, the most recent figure standing at 21.5% for Q2 2023.

In Q2 2023, Net Margin changed N/A year-over-year to 21.5%; the TTM figure through Jun 2023 stood at 0.0% (changed N/A YoY), while the FY2026 annual figure was 12.74%, down 466.0% from the prior year.
Net Margin for Q2 2023 stood at 21.5%, up from 20.84% in the prior quarter.
The five-year high for Net Margin was 22.73% in Q2 2019, with the low at 16.0% in Q3 2020.
The 5-year median for Net Margin is 17.25% (2021), against an average of 12.07%.
Peak annual rise in Net Margin reached 957 bps in 2019, while the deepest fall reached 2560 bps in 2019.
Dr Reddys Laboratories' Net Margin stood at 13.03% in 2019, then fell by 23 bps to 16.0% in 2020, then surged by 208 bps to 17.25% in 2021, then slipped by 12 bps to 15.25% in 2022, then soared by 41 bps to 21.5% in 2023.
Business Quant data shows RDY's Net Margin at 21.5% in Q2 2023, 20.84% in Q1 2023, and 15.25% in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Haleon	43.65 Bn	42.68 Bn	-	-
2	Teva Pharmaceutical Industries	43.09 Bn	39.44 Bn	2.15 Bn	-13.91%
3	Zoetis	31.54 Bn	29.86 Bn	1.05 Bn	35.09%
4	Takeda Pharmaceutical	28.61 Bn	22.81 Bn	5.10 Bn	9.28%
5	United Therapeutics	22.11 Bn	19.45 Bn	683.80 Mn	42.51%
6	Viatris	18.77 Bn	17.88 Bn	1.46 Bn	-3.16%
7	Neurocrine Biosciences	15.62 Bn	15.23 Bn	935.80 Mn	15.06%
8	Elanco Animal Health	12.07 Bn	11.54 Bn	798.00 Mn	3.95%
9	Dr Reddys Laboratories	10.09 Bn	9.93 Bn	-	-
10	Alkermes	8.20 Bn	7.54 Bn	397.90 Mn	0.11%

Download Data